OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
2006
129
LTM Revenue $94.8M
LTM EBITDA $11.9M
$174M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
OptimizeRx has a last 12-month revenue of $94.8M and a last 12-month EBITDA of $11.9M.
In the most recent fiscal year, OptimizeRx achieved revenue of $92.1M and an EBITDA of -$8.9M.
OptimizeRx expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See OptimizeRx valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $71.5M | $92.1M | XXX | XXX | XXX |
Gross Profit | $39.0M | $42.9M | XXX | XXX | XXX |
Gross Margin | 54% | 47% | XXX | XXX | XXX |
EBITDA | -$21.3M | -$8.9M | XXX | XXX | XXX |
EBITDA Margin | -30% | -10% | XXX | XXX | XXX |
Net Profit | -$11.4M | -$17.6M | XXX | XXX | XXX |
Net Margin | -16% | -19% | XXX | XXX | XXX |
Net Debt | n/a | $22.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, OptimizeRx's stock price is $8.
OptimizeRx has current market cap of $154M, and EV of $174M.
See OptimizeRx trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$174M | $154M | XXX | XXX | XXX | XXX | $0.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, OptimizeRx has market cap of $154M and EV of $174M.
OptimizeRx's trades at 1.8x LTM EV/Revenue multiple, and 14.6x LTM EBITDA.
Analysts estimate OptimizeRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for OptimizeRx and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $174M | XXX | XXX | XXX |
EV/Revenue | 1.9x | XXX | XXX | XXX |
EV/EBITDA | -19.5x | XXX | XXX | XXX |
P/E | -7.7x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | 39.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOptimizeRx's NTM/LTM revenue growth is 10%
OptimizeRx's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, OptimizeRx's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate OptimizeRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for OptimizeRx and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 29% | XXX | XXX | XXX | XXX |
EBITDA Margin | -10% | XXX | XXX | XXX | XXX |
EBITDA Growth | -58% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 1% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 67% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | 71% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OptimizeRx acquired XXX companies to date.
Last acquisition by OptimizeRx was XXXXXXXX, XXXXX XXXXX XXXXXX . OptimizeRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was OptimizeRx founded? | OptimizeRx was founded in 2006. |
Where is OptimizeRx headquartered? | OptimizeRx is headquartered in United States of America. |
How many employees does OptimizeRx have? | As of today, OptimizeRx has 129 employees. |
Who is the CEO of OptimizeRx? | OptimizeRx's CEO is Mr. Stephen L. Silvestro. |
Is OptimizeRx publicy listed? | Yes, OptimizeRx is a public company listed on NAS. |
What is the stock symbol of OptimizeRx? | OptimizeRx trades under OPRX ticker. |
When did OptimizeRx go public? | OptimizeRx went public in 2009. |
Who are competitors of OptimizeRx? | Similar companies to OptimizeRx include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
What is the current market cap of OptimizeRx? | OptimizeRx's current market cap is $154M |
What is the current revenue of OptimizeRx? | OptimizeRx's last 12-month revenue is $94.8M. |
What is the current EBITDA of OptimizeRx? | OptimizeRx's last 12-month EBITDA is $11.9M. |
What is the current EV/Revenue multiple of OptimizeRx? | Current revenue multiple of OptimizeRx is 1.8x. |
What is the current EV/EBITDA multiple of OptimizeRx? | Current EBITDA multiple of OptimizeRx is 14.6x. |
What is the current revenue growth of OptimizeRx? | OptimizeRx revenue growth between 2023 and 2024 was 29%. |
Is OptimizeRx profitable? | Yes, OptimizeRx is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.